BeiGene Q3 revenue $781M (+102% YoY); net income of $215M vs loss of $558M last year

BeOne Medicines Ltd.

2023-Q3 EPS reported -$0.38 revenue$1,824,370,000

Global product sales up 70% to $595M; BRUKINSA sales $358M (+130%) led by US launch momentum.
Net income $215M vs net loss $558M in Q3 2022; operating loss improved by $304M YoY.
Total revenue $781M (+102%); US revenue $398M, China $288M, Europe $86M.
Gross margin improved to 83.8% from 78.1% on higher-mix BRUKINSA and lower tislelizumab costs.
Cash $3.2B; TEVIMBRA approved in EU, US BLA accepted for ESCC with PDUFA July 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeOne Medicines Ltd. reported the three months ended September 30, 2023 results: revenue total revenue of $781 million, net income Net Income ... $215.4 million.

Period: the three months ended September 30, 2023
Revenue: total revenue of $781 million
Net income: Net Income ... $215.4 million
Result: reported results

Exact text from the filing

Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates • Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage • Global sales of BRUKINSA

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-23-000163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.